OKYO Pharma Limited OKYO
As ofNov 20, 2026, 3:13 PM EST
- YTD
- -46.08%
- 1 year
- -41.57%
- Market cap
- 57.99M
- EPS (ttm)
- -0.24
- Shares out
- 33.84M
- YTD return
- -46.08%
- 1-year return
- -41.57%
- 50-day average
- 1.08
- 200-day average
- 1.23
- Enterprise value
- 34.04M
- Volume
- 51.84K
- Avg volume
- 142.45K
- Open
- 1.18
- Previous close
- 1.16
- Day's range
- 1.09 – 1.18
- 52-week range
- 1.00 – 3.20
- Beta
- -3.36
- Price target
- 7.00 (+527.2%)
Key statistics
- Free cash flow
- -3.09M
- Total cash
- 4.05M
- Total debt
- 2.22M
- Short % of float
- 1.00%
Fundamental scorecard
4 of 25 checks passed on OKYO’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Mar 31, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About OKYO Pharma Limited
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- okyopharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on OKYO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Barclays Plc | 2.84% | 961,000 | 1.02M | Sep 29, 2024 |
| Cerity Partners LLC | 0.04% | 12,812 | 13.58K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.04% | 12,090 | 12.81K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.04% | 14,876 | 15.77K | Sep 29, 2024 |
| UBS Group AG | 0.00% | 525 | 556 | Sep 29, 2024 |
| Continuum Advisory, Llc | 0.00% | 50 | 52 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.04% | 12,090 | 12.81K | Oct 30, 2024 |
